Search tips
Search criteria 


Logo of jnmaLink to Publisher's site
J Natl Med Assoc. 2005 August; 97(8): 1143–1154.
PMCID: PMC2576013

Preparing African-American men in community primary care practices to decide whether or not to have prostate cancer screening.


BACKGROUND: This study was a randomized trial to test the impact of an informed decision-making intervention on prostate cancer screening use. METHODS: The study population included 242 African-American men from three primary care practices who were 40-69 years of age and had no history of prostate cancer. Participants completed a baseline survey questionnaire and were randomly assigned either to a Standard Intervention (SI) group (N=121) or an Enhanced Intervention (EI) group (N=121). An informational booklet was mailed to both groups. EI group men were also offered a screening decision education session. Two outcomes were considered: (1) complete screening (i.e., having a digital rectal exam (DRE) and prostate specific antigen (PSA) testing), and (2) complete or partial screening (i.e., having a PSA test with or without DRE). An endpoint chart audit was performed six months after initial intervention contact. The data were analyzed via exact logistic regression. RESULTS: Overall, screening use was low among study participants. EI group men had a screening frequency two times greater than that of SI group men, but the difference was not statistically significant: 8% vs. 4 % (OR = 1.94) fo rcomplete screening, and 19% vs. 10% (OR = 2.08) for complete or partial screening. Multivariable analyses showed that being in the EI group and primary care practice were significant predictors of complete or partial screening (OR = 3.9 and OR = 5.64, respectively). CONCLUSION: Prostate cancer screening use may be influenced by exposure to decision education and the influence of screening-related primary care practice factors.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Jemal Ahmedin, Murray Taylor, Ward Elizabeth, Samuels Alicia, Tiwari Ram C, Ghafoor Asma, Feuer Eric J, Thun Michael J. Cancer statistics, 2005. CA Cancer J Clin. 2005 Jan-Feb;55(1):10–30. [PubMed]
  • Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993 Aug 25;270(8):948–954. [PubMed]
  • Walsh PC, Brooks JD. The Swedish prostate cancer paradox. JAMA. 1997 Feb 12;277(6):497–498. [PubMed]
  • Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG, Jr, Wennberg JE. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch Fam Med. 1993 May;2(5):487–493. [PubMed]
  • Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, Brook RH. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995 Jan 11;273(2):129–135. [PubMed]
  • Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol. 1994 Nov;152(5 Pt 2):1905–1909. [PubMed]
  • Lilleby W, Fosså SD, Waehre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):735–743. [PubMed]
  • Meredith P, Emberton M, Wood C. New directions in information for patients. BMJ. 1995 Jul 1;311(6996):4–5. [PMC free article] [PubMed]
  • Screening for prostate cancer: recommendation and rationale. Ann Intern Med. 2002 Dec 3;137(11):915–916. [PubMed]
  • Sheridan Stacey L, Harris Russell P, Woolf Steven H. Shared decision making about screening and chemoprevention. a suggested approach from the U.S. Preventive Services Task Force. Am J Prev Med. 2004 Jan;26(1):56–66. [PubMed]
  • Ubel PA. Informed consent. From bodily invasion to the seemingly mundane. Arch Intern Med. 1996 Jun 24;156(12):1262–1263. [PubMed]
  • Barry Michael J. Health decision aids to facilitate shared decision making in office practice. Ann Intern Med. 2002 Jan 15;136(2):127–135. [PubMed]
  • Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993 Jan-Feb;43(1):42–46. [PubMed]
  • Vernon SW, Myers RE, Tilley BC. Development and validation of an instrument to measure factors related to colorectal cancer screening adherence. Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):825–832. [PubMed]
  • Myers RE, Chodak GW, Wolf TA, Burgh DY, McGrory GT, Marcus SM, Diehl JA, Williams M. Adherence by African American men to prostate cancer education and early detection. Cancer. 1999 Jul 1;86(1):88–104. [PubMed]
  • Myers RE, Ross E, Jepson C, Wolf T, Balshem A, Millner L, Leventhal H. Modeling adherence to colorectal cancer screening. Prev Med. 1994 Mar;23(2):142–151. [PubMed]
  • Carter WB, Beach LR, Inui TS, Kirscht JP, Prodzinski JC. Developing and testing a decision model for predicting influenza vaccination compliance. Health Serv Res. 1986 Feb;20(6 Pt 2):897–932. [PMC free article] [PubMed]
  • Dolan James G. Involving patients in decisions regarding preventive health interventions using the analytic hierarchy process. Health Expect. 2000 Mar;3(1):37–45. [PubMed]
  • Dolan James G, Frisina Susan. Randomized controlled trial of a patient decision aid for colorectal cancer screening. Med Decis Making. 2002 Mar-Apr;22(2):125–139. [PubMed]
  • O'Connor AM, Rostom A, Fiset V, Tetroe J, Entwistle V, Llewellyn-Thomas H, Holmes-Rovner M, Barry M, Jones J. Decision aids for patients facing health treatment or screening decisions: systematic review. BMJ. 1999 Sep 18;319(7212):731–734. [PMC free article] [PubMed]
  • Molenaar S, Sprangers MA, Postma-Schuit FC, Rutgers EJ, Noorlander J, Hendriks J, de Haes HC. Feasibility and effects of decision aids. Med Decis Making. 2000 Jan-Mar;20(1):112–127. [PubMed]
  • Myers RE, Kunkel EJ. Preparatory education for informed decision-making in prostate cancer early detection and treatment. Semin Urol Oncol. 2000 Aug;18(3):172–177. [PubMed]
  • Emery J. Is informed choice in genetic testing a different breed of informed decision-making? A discussion paper. Health Expect. 2001 Jun;4(2):81–86. [PubMed]
  • Davison BJ, Kirk P, Degner LF, Hassard TH. Information and patient participation in screening for prostate cancer. Patient Educ Couns. 1999 Jul;37(3):255–263. [PubMed]
  • Volk Robert J, Spann Stephen J, Cass Alvab R, Hawley Sarah T. Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up. Ann Fam Med. 2003 May-Jun;1(1):22–28. [PubMed]
  • Myers RE, Chodak GW, Wolf TA, Burgh DY, McGrory GT, Marcus SM, Diehl JA, Williams M. Adherence by African American men to prostate cancer education and early detection. Cancer. 1999 Jul 1;86(1):88–104. [PubMed]
  • Weinrich SP, Boyd MD, Weinrich M, Greene F, Reynolds WA, Jr, Metlin C. Increasing prostate cancer screening in African American men with peer-educator and client-navigator interventions. J Cancer Educ. 1998 Winter;13(4):213–219. [PubMed]
  • Wilt TJ, Paul J, Murdoch M, Nelson D, Nugent S, Rubins HB. Educating men about prostate cancer screening. A randomized trial of a mailed pamphlet. Eff Clin Pract. 2001 May-Jun;4(3):112–120. [PubMed]
  • Schapira MM, VanRuiswyk J. The effect of an illustrated pamphlet decision-aid on the use of prostate cancer screening tests. J Fam Pract. 2000 May;49(5):418–424. [PubMed]
  • Wolf AM, Nasser JF, Wolf AM, Schorling JB. The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med. 1996 Jun 24;156(12):1333–1336. [PubMed]
  • Wolf AM, Philbrick JT, Schorling JB. Predictors of interest in prostate-specific antigen screening and the impact of informed consent: what should we tell our patients? Am J Med. 1997 Oct;103(4):308–314. [PubMed]
  • Flood AB, Wennberg JE, Nease RF, Jr, Fowler FJ, Jr, Ding J, Hynes LM. The importance of patient preference in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team. J Gen Intern Med. 1996 Jun;11(6):342–349. [PubMed]
  • Volk RJ, Cass AR, Spann SJ. A randomized controlled trial of shared decision making for prostate cancer screening. Arch Fam Med. 1999 Jul-Aug;8(4):333–340. [PubMed]
  • Frosch DL, Kaplan RM, Felitti V. The evaluation of two methods to facilitate shared decision making for men considering the prostate-specific antigen test. J Gen Intern Med. 2001 Jun;16(6):391–398. [PMC free article] [PubMed]
  • Chan Evelyn C Y, Vernon Sally W, O'Donnell Frederick T, Ahn Chul, Greisinger Anthony, Aga Donnie W. Informed consent for cancer screening with prostate-specific antigen: how well are men getting the message? Am J Public Health. 2003 May;93(5):779–785. [PubMed]
  • Stamey Thomas A, Caldwell Mitchell, McNeal John E, Nolley Rosalie, Hemenez Marci, Downs Joshua. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004 Oct;172(4 Pt 1):1297–1301. [PubMed]
  • Franks Peter, Fiscella Kevin, Beckett Laurel, Zwanziger Jack, Mooney Cathy, Gorthy ShihFangHuang. Effects of patient and physician practice socioeconomic status on the health care of privately insured managed care patients. Med Care. 2003 Jul;41(7):842–852. [PubMed]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association